Harrison & Star lands Roche Pegasys account

Share this article:
Roche switched professional agencies for its top-selling hepatitis C therapy Pegasys to Omnicom’s Harrison & Star from echo Torre Lazur, part of Interpublic Group’s McCann Healthcare Worldwide. The move followed a three-way pitch among Harrison & Star, GSW and one other agency. Pegasys is the world’s best-selling treatment for chronic hepatitis C. The drug brought in $1.13 billion in revenue last year, a 17% increase over 2004.
Share this article:

Email Newsletters

More in News

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi tightens PCSK9 race, exceeds Q2 expectations

Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.

HHS shows how diabetes adds up

HHS shows how diabetes adds up

A 2005-to-2010 survey shows diabetics 65-and-up juggle at least four co-morbid conditions and five medications for them.

AstraZeneca beefs up respiratory portfolio

AstraZeneca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.